Hallucinogens
Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens
Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder
Cybin’s Psychedelic Drug CYB003 Demonstrates Sustained Efficacy in Reducing Depression Symptoms Over 12 Months
CYB003, psychedelic drug, depression treatment, sustained efficacy, 12-month symptom reduction, major depressive disorder (MDD), psilocin analog.
Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments
Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.
Psyence Biomed to Acquire Clairvoyant Therapeutics, Expanding Psilocybin-Based Therapeutic Pipeline
Psilocybin, Psyence Biomed, Clairvoyant Therapeutics, Acquisition, Alcohol Use Disorder (AUD), Clinical Trials, Psychedelic Therapeutics
AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership
AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.